Balstilimab

巴替利单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameBalstilimab
Drug Alias NameBAL (Agenus/Ludwig Institute for Cancer Research)RebmAb-700AGEN2034AGEN-2034
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsEsophageal adenocarcinomaSolid tumoursMicrosatellite Instability +[33] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumArmeniaCanada +[22] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAgenus IncLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesAgenus IncZydus Lifesciences LtdImmune Oncology Research Institute +[9] 
Inactive CompaniesUT Health San AntonioGroupe Oncologie Radiotherapie Tete Et CouThe University Of Texas MD Anderson Cancer Center
Active IndicationsEsophageal adenocarcinomaSolid tumoursMicrosatellite Instability +[25] 
Inactive IndicationsUrinary Bladder NeoplasmsOropharyngeal NeoplasmsHead and Neck Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A